Furthermore, targeting KRAS expression, in patients who had KRAS mutant tumours, failed to enhance tumour sensitivity to panitumumab, suggesting that statins could not be used to modulate drug sensitivity in tumours with mutant KRAS (Baas et al, 2015). This evidence concerns the gene KRAS and neoplasm.